PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1618296
PUBLISHER: Market Xcel - Markets and Data | PRODUCT CODE: 1618296
Global urology devices market is projected to witness a CAGR of 6.11% during the forecast period 2025-2032, growing from USD 40.05 billion in 2024 to USD 64.37 billion in 2032. The market demand for urology devices is anticipated to thrive drastically in the forecast years due to the increasing prevalence of urological diseases and surgical procedures for their treatment, as well as the growing interest of investors in the urology devices market.
Urology devices help diagnose and treat various medical conditions, such as male and female urinary tract and male reproductive systems. These instruments are put to use by Urologists in the diagnosis and treatment of various disorders ranging from those managed with simple techniques to complex surgical procedures such as kidney stones, urinary incontinence, and prostate conditions, among others. Urologists rely on several common instruments, such as cystoscopes for the therapeutic inspection of the bladder, ureteral stents for managing kidney obstruction, and resectoscopes for bladder neoplasms. Urological techniques consist of laparoscopic surgery, lasers, and other endoscopic approaches. Additionally, the urology devices market is experiencing significant growth driven by various factors, including advancements in urology products and increased awareness of growth in the urology devices market.
For instance, in October 2023, Teleflex Incorporated completed the acquisition of Palette Life Sciences AB, adding the biodegradable sculptable rectal spacer, Barrigel, to the former's urology product portfolio. Under the agreement terms, the deal was closed after an upfront payment of USD 600 million. The deal is expected to aid Telefex in expanding its presence in the urology care sector and allow it to provide essential diagnostic tools to healthcare providers to enhance patient care.
Increasing Prevalence of Urological Diseases
Growth in the urology devices market can be attributed largely to the rising incidence rates of several urological diseases, of which prostate cancer, urinary incontinence, kidney stones, and benign prostatic hyperplasia (BPH) are the most common. As the world demographics continue to age, likely, more of the older adults who are more prone to the affections of urological health will have these conditions, and so the rates of occurrence will rise. Governments, through their health policies and educational campaigns targeting patients, have also increased the awareness of urological conditions, and this is also facilitating early diagnosis and treatment. Thus, the market for innovative urology devices is expected to grow even more in the forecast period, owing to rising demand for early interventions. For instance, in January 2024, Boston Scientific Corporation announced a definitive agreement to acquire Axonics, Inc., a medical technology firm specializing in urinary and bowel dysfunction devices. The acquisition, valued at USD 71 per share or approximately USD 3.7 billion, will add Axonics sacral neuromodulation (SNM) systems. SNM therapy, a minimally invasive procedure using mild electrical pulses to treat overactive bladder (OAB) and fecal incontinence, has shown significant improvements in patients' quality of life. This acquisition expands Boston Scientific's presence in the high-growth SNM market and enhances its support for urologists managing chronic conditions.
Rising Research and Development Activities Boosts Market Demand
The increasing investments by the leading medical technology companies and research institutions across the globe to bolster the development and availability of novel urology devices is providing lucrative growth opportunities to the urology devices market. In April 2024, UnivLabs Technologies Pvt Ltd partnered with Indian Institute of Technology (IIT) Roorkee to translate research findings into devices with real world applications in the field of urology care. The partnership aims to support the commercialization and development of products developed by the educational institute with the help of resources from UnivLabs. IIT Roorkee's patented technology is based on ureteral stents that are often used for maintaining fluid drainage which is often obstructed due to post operative infection and swelling, tumors, kidney stones, and blood clot.
Additionally, the rising emphasis on research and development activities can also be attributed to the growing demand for urology devices that enhance both physician and patient convenience due to the rising incidences of urological disorders across the globe. Leading medical device companies are also investing in research and development activities to support technological innovations and bolster the development of devices with enhanced diagnostic abilities, positively influencing the expansion of the market.
Kidney Diseases to Dominate the Urology Devices Market
The kidney diseases segment to dominate the urology devices market is expected to be dominated by the prevalence of kidney diseases, including renal cancer, kidney stones, and chronic kidney disease (CKD). The need for efficient diagnosis and treatment for kidney-related diseases is growing as the population ages, and the prevalence of risk factors is linked to lifestyle changes. Advanced lithotripsy systems, endoscopic procedures, and renal replacement therapies are just a few of the urology equipment innovations that are expanding treatment options and increasing patient results. Furthermore, early detection and treatments are being made easier by greater awareness of kidney diseases and examination initiatives; the kidney diseases market is anticipated to take a sizable portion of the urology devices market as healthcare professionals concentrate on enhancing renal health management and patient care.
For instance, in April 2024, Dornier MedTech, an Advanced MedTech Holdings Limited subsidiary, launched UroGPT, an innovative AI tool designed to support kidney stone patients. This groundbreaking initiative underscores the company's commitment to digital innovation in patient-centered healthcare solutions. Developed in collaboration with leading urologists, UroGPT offers patients on-demand advice and actionable insights, enhancing their understanding and management of kidney stone conditions.
North America Dominates the Urology Devices Market
North American region is anticipated to dominate the urology devices market due to several reasons, including strong healthcare infrastructure, high prevalence of urological diseases, and high investments in research and development. The region benefits from a strong presence of major urology device manufacturers and continuous innovations that expand diagnostic and treatment options. Additionally, growing awareness about urological diseases and the availability of specialized care are contributing to increased demand for urological devices. The aging population, coupled with increasing rates of obesity and diabetes (key risk factors for urological disorders), is further fueling the market growth. For instance, in April 2024, Olympus Corporation received United States FDA 510(k) clearance for its first single use ureteroscope system, RenaFlex; this innovative system is designed for accessing and visualizing the urinary tract to diagnose and treat disorders such as kidney stones. The RenaFlex ureteroscope facilitates the visualization of various urinary tract organs and cavities through transurethral or percutaneous access routes. Key benefits of the RenaFlex single-use ureteroscope include improved infection control, reduced sterilization costs, and enhanced procedural efficiency, positioning it as a valuable tool for urologists in managing urinary diseases.
Future Market Scenario (2025-2032F)
As per the global urology devices market analysis, the market is expected to witness significant growth over the forecast period due to the rising incidences of urological diseases, rapid expansion of the healthcare sector in various regions, and increasing investments in product innovation. Additionally, the growing efforts of the key players of the market towards novel product launches and expansion of their global presence is also expected to boost the global urology devices market size. Furthermore, increasing research and development activities to assess the functioning and efficacy of different urology devices and procedures is also supporting the growth of the market. Ethicon Endo-Surgery (Johnson & Johnson Services, Inc.) is starting an observational study in January 2025 to assess the safety and demonstrate the performance of HARMONIC 700 Shears device for use in adult and pediatric surgical procedures. The study is expected to conclude in August 2026. Such studies are expected to aid the key players of the market in demonstrating the working and safety of their products, allowing them to launch novel devices and expand their market share.
Key Players Landscape and Outlook
The market's growth is bolstered by the increasing investments by the companies towards mergers and acquisitions and partnerships and collaborations to boost their product portfolio and expand their geographical presence, novel product launches, and increasing approvals from different regulatory bodies.
For instance, in September 2024, Olympus Corporation, one of the leading medical technology companies, launched CH-S700-08-LB, a new 4K camera head for gynecology and endoscopic urology procedures in Europe, with plans to launch the product in Singapore, Hong Kong, and Japan after receiving approvals from each country's regulatory bodies. Developed through a joint venture between Sony Corporation and Olympus Corporation, the camera head is compatible with the Visera Elite III video system and offers four times the resolution compared to conventional HD cameras. With such launches, Olympus aims to improve patient outcomes as enhanced imaging solutions allow for early diagnosis of urological conditions, including bladder cancer.
Additionally, in August 2023, Fresenius Medical Care AG & Co. KGaA received 510(k) clearance from the United States FDA for VersiHD with GuideMe Software, a self-guided interface for its VersiHD home hemodialysis (HHD) system. The GuideMe Software offers graphical guidance to simplify use, boost patient and physician confidence, and streamline training, thus providing a smoother transition to home dialysis and improving the overall patient experience.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.